Charles Mc Wherter Cyma Bay Therapeutics, Inc. (CBAY) insider trading activity

CBAY Quotes by TradingView

Charles Mc Wherter is President of R&D of CymaBay Therapeutics, Inc.. Currently has a direct ownership of 0 shares of CBAY, which is worth approximately $0. The most recent transaction as insider was on Mar 22, 2024, when has been sold 46,938 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
100.0% 3M change
100.0% 12M change
Total Value Held $0

Charles McWherter Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 22 2024
SELL
Sale (or disposition) back to the issuer
-
46,938 Reduced 100.0%
0 Common Stock
Jan 24 2024
BUY
Grant, award, or other acquisition
-
31,938 Added 40.49%
46,938 Common Stock
Jan 19 2024
SELL
Open market or private sale
$435,599 $23.67 p/Share
18,403 Reduced 55.09%
15,000 Common Stock
Jan 19 2024
BUY
Exercise of conversion of derivative security
$96,799 $5.26 p/Share
18,403 Added 50.38%
18,125 Common Stock
Dec 18 2023
SELL
Open market or private sale
$243,524 $21.49 p/Share
11,332 Reduced 43.04%
15,000 Common Stock
Dec 18 2023
BUY
Exercise of conversion of derivative security
$56,660 $5.0 p/Share
11,332 Added 34.51%
21,504 Common Stock
Nov 17 2023
SELL
Open market or private sale
$207,331 $18.28 p/Share
11,342 Reduced 43.06%
15,000 Common Stock
Nov 17 2023
BUY
Exercise of conversion of derivative security
$56,710 $5.0 p/Share
11,342 Added 30.1%
26,342 Common Stock
Oct 18 2023
SELL
Open market or private sale
$305,924 $14.07 p/Share
21,743 Reduced 59.18%
15,000 Common Stock
Oct 18 2023
BUY
Exercise of conversion of derivative security
$108,715 $5.0 p/Share
21,743 Added 37.18%
36,743 Common Stock
Sep 18 2023
SELL
Open market or private sale
$352,720 $16.22 p/Share
21,746 Reduced 59.18%
15,000 Common Stock
Sep 18 2023
BUY
Exercise of conversion of derivative security
$108,730 $5.0 p/Share
21,746 Added 37.18%
36,746 Common Stock
Aug 18 2023
SELL
Open market or private sale
$249,426 $11.47 p/Share
21,746 Reduced 59.18%
15,000 Common Stock
Aug 18 2023
BUY
Exercise of conversion of derivative security
$108,730 $5.0 p/Share
21,746 Added 37.18%
36,746 Common Stock
Jul 18 2023
SELL
Open market or private sale
$248,591 $11.43 p/Share
21,749 Reduced 59.18%
15,000 Common Stock
Jul 18 2023
BUY
Exercise of conversion of derivative security
$108,745 $5.0 p/Share
21,749 Added 37.18%
36,749 Common Stock
Jun 20 2023
SELL
Open market or private sale
$177,471 $8.16 p/Share
21,749 Reduced 59.18%
15,000 Common Stock
Jun 20 2023
BUY
Exercise of conversion of derivative security
$108,745 $5.0 p/Share
21,749 Added 37.18%
36,749 Common Stock
May 18 2023
SELL
Open market or private sale
$197,480 $9.08 p/Share
21,749 Reduced 59.18%
15,000 Common Stock
May 18 2023
BUY
Exercise of conversion of derivative security
$108,745 $5.0 p/Share
21,749 Added 37.18%
36,749 Common Stock
CM

Charles Mc Wherter

President of R&D
Newark, CA

Track Institutional and Insider Activities on CBAY

Follow CymaBay Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CBAY shares.

Notify only if

Insider Trading

Get notified when an Cyma Bay Therapeutics, Inc. insider buys or sells CBAY shares.

Notify only if

News

Receive news related to CymaBay Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CBAY